Articles

November 1, 2019 – Taiho Oncology Joins Efforts To Improve Awareness Of Gastric Cancer With Support Of Leading Advocacy Groups

Recognizing a need for greater awareness and education around gastric cancer, Taiho Oncology, Inc., today announced its support of four leading gastric cancer advocacy organizations in observance of National Gastric Cancer Awareness Month. The company is sponsoring patient and caregiver programs, education and research throughout 2019 on behalf of Debbie’s Dream Foundation, the Gastric Cancer…

October 14, 2019 – ANALYSIS OF PATIENTS WITH PRIOR GASTRECTOMY TREATED WITH LONSURF® (TRIFLURIDINE AND TIPIRACIL) PUBLISHED IN JAMA ONCOLOGY

Taiho Oncology, Inc. announced today that detailed results from the analysis of patients with prior gastrectomy enrolled in the Phase 3 TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine and tipiracil) in adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane…

July 3, 2019 – Gastric Cancer Rates Higher Among Patients Treated For H. Pylori

Patients who receive antibiotic treatment for Helicobacter pylori infection experience gastric cancer at rates higher than the general population and several risk factors can increase that risk even further, according to data presented at Digestive Disease Week. View Full Article

July 4, 2019 – Study Uncovers Origin of Cell Layer that Hides Stomach Cancer

A group of researchers from Hiroshima recently discovered the origin of a normal-looking stomach lining that covers sites of gastric cancer and makes it difficult to spot after the eradication of an H. pylori infection. H. pylori infection is a major cause of stomach cancer and causes inflammation by releasing substances that can destroy cells…

February 25, 2019 – Defense Health Program Department of Defense Peer Reviewed Cancer Research Program Funding Opportunities for Fiscal Year 2019 (FY19)

The FY19 Defense Appropriation provides $90 million (M) to the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP)…

February 25, 2019 – FDA Approves Taiho Oncology’s LONSURF® (trifluridine/tipiracil) for Adult Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Taiho Oncology, Inc. today announced that the United States Food and Drug Administration (FDA) has approved LONSURF® as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy.…

January 7, 2019 – Clinical trial to develop breath test for multiple cancers

UK researchers have recently launched a new clinical trial to develop a breath test that could help detect multiple cancer types. This technology could help doctors detect and diagnose cancers earlier by measuring volatile organic compounds (VOCs) through breath biopsy. Depending on conditions, cells can release different patterns of VOCs, and this trial sets out…

October 26, 2018 – FDA Accepts Supplemental New Drug Application for the Treatment of Metastatic Gastric/Gastroesophageal Junction (GEJ) Adenocarcinoma

Taiho Oncology announced that the FDA has granted priority review for the supplemental New Drug Application (sNDA) for LONSURF as new treatment for patients with previously treated advanced or metastatic gastric adenocarcinoma. The drug trial met its primary goal of prolonged overall survival and secondary endpoint measurements of progression-free survival (PFS) in addition to consistent…

September 12, 2018 – H. pylori test hints at risk factor for stomach cancer

Helicobacter pylori, a specific strain of bacteria found more often in East Asian patients may be a risk factor for stomach cancer. Doctors want to identify who is most at risk for cancer carrying out a pilot study that would shape treatment and screening strategies for patients infected with this bacterium. Dr. Nina Salama considers…

August 30, 2018- Mutations in MUC16 Gene May Help Define Immunotherapy Strategies for Gastric Cancer, Study Suggests

Understanding the mutation in the MUC16 gene may be vital to help predict the outcome of the disease as well as possible treatments available for gastric cancer patients. The MUC16 mutation is thought to increase cancer cell’s susceptibility to immunotherapies. Although the genetics of gastric cancer varies greatly from person to person, mutations in the…